According to a report examining how informed consent is given to participants in the COVID-19 vaccine trial, disclosure forms fail to warn volunteers that if they are exposed to the virus, the vaccine may render them vulnerable to more serious disease.
The report, “Informed Consent Disclosure to Vaccine Trial Subjects of Risk of COVID-19 Vaccine Worsening Clinical Disease,” published in the International Journal of Clinical Practice, October 28, 2020, points out that “COVID-19 vaccines designed to elicit neutralizing antibodies may sensitize vaccine recipients to more severe disease than if they were not vaccinated.”
“Vaccines for SARS, MERS and RSV have never been approved, and the data generated in the development and testing of these vaccines suggest a serious mechanistic concern: that vaccines designed empirically using the traditional approach (consisting of the unmodified or minimally modified coronavirus viral spike to elicit neutralizing antibodies), be they composed of protein, viral vector, DNA or RNA and irrespective of delivery method, may worsen COVID-19 disease via antibody-dependent enhancement (ADE),” the paper states.
“This risk is sufficiently obscured in clinical trial protocols and consent forms for ongoing COVID-19 vaccine trials that adequate patient comprehension of this risk is unlikely to occur, obviating truly informed consent by subjects in these trials.
The specific and significant COVID-19 risk of ADE should have been and should be prominently and independently disclosed to research subjects currently in vaccine trials, as well as those being recruited for the trials and future patients after vaccine approval, in order to meet the medical ethics standard of patient comprehension for informed consent.”
What Is Antibody-Dependent Enhancement?
Previous coronavirus vaccine attempts for extreme acute respiratory syndrome coronavirus (SARS-CoV), Middle East respiratory syndrome coronavirus (MERS-CoV) and respiratory syncytial virus (RSV) have disclosed a serious problem, as reported by the authors of the International Journal of Clinical Practice paper: vaccines tend to cause antibody-dependent enhancement.
What does that mean exactly? In a nutshell, it means that the vaccination simply increases the capacity of the virus to penetrate and kill the cells, resulting in more serious disease than if you had not been vaccinated, rather than improving your immunity against the infection.
This is the absolute reverse of what a vaccine is intended to do, and a major concern that has been pointed out for a COVID-19 vaccine from the very beginning of this push. The “Antibody-Dependent Enhancement of Virus Infection and Disease” 2003 review paper describes it this way:
“In general, virus-specific antibodies are considered antiviral and play an important role in the control of virus infections in a number of ways. However, in some instances, the presence of specific antibodies can be beneficial to the virus. This activity is known as antibody-dependent enhancement (ADE) of virus infection.
The ADE of virus infection is a phenomenon in which virus-specific antibodies enhance the entry of virus, and in some cases the replication of virus, into monocytes/macrophages and granulocytic cells through interaction with Fc and/or complement receptors.
This phenomenon has been reported in vitro and in vivo for viruses representing numerous families and genera of public health and veterinary importance. These viruses share some common features such as preferential replication in macrophages, ability to establish persistence, and antigenic diversity. For some viruses, ADE of infection has become a great concern to disease control by vaccination.”
Immune Strengthening is a Major Concern
Another paper worth mentioning is the May 2020 mini review “Impact of Immune Enhancement on COVID-19 Polyclonal Hyperimmune Globulin Therapy and Vaccine Development.” As in many other papers, the authors point out that:
“While development of both hyperimmune globulin therapy and vaccine against SARS-CoV-2 are promising, they both pose a common theoretical safety concern. Experimental studies have suggested the possibility of immune-enhanced disease of SARS-CoV and MERS-CoV infections, which may thus similarly occur with SARS-CoV-2 infection …
Immune enhancement of disease can theoretically occur in two ways. Firstly, non-neutralizing or sub-neutralizing levels of antibodies can enhance SARS-CoV-2 infection into target cells.
Secondly, antibodies could enhance inflammation and hence severity of pulmonary disease. An overview of these antibody dependent infection and immunopathology enhancement effects are summarized in Fig. 1 …
Currently, there are multiple SARS-CoV and MERS-CoV vaccine candidates in pre-clinical or early phase clinical trials. Animal studies on these CoVs have shown that the spike (S) protein-based vaccines (specifically the receptor binding domain, RBD) are highly immunogenic and protective against wild-type CoV challenge.
Vaccines that target other parts of the virus, such as the nucleocapsid, without the S protein, have shown no protection against CoV infection and increased lung pathology. However, immunization with some S protein based CoV vaccines have also displayed signs of enhanced lung pathology following challenge.
Hence, besides the choice of antigen target, vaccine efficacy and risk of immunopathology may be dependent on other ancillary factors, including adjuvant formulation, age at vaccination … and route of immunization.”
Do a Risk-Benefit Calculation Before You Make A Decision
In all probability, they will be released to the public in a reasonably short order, regardless of how effective (or ineffective) the COVID-19 vaccines end up being. Most forecast that sometime in 2021 one or more vaccines will be ready.
Ironically, a mass vaccine mandate is no longer endorsed, given that COVID-19’s lethality is lower than influenza for people under the age of 60. If you are under the age of 40, the risk of dying from COVID-19 is just 0.01 percent, which means that you have a 99.99 percent chance of surviving the infection. And if you’re metabolically flexible and vitamin D replete, you could increase it to 99.999 percent.
So, exactly, what are we defending the COVID-19 vaccine against? Vaccines, as mentioned, are not even meant to prevent infection, only to reduce the severity of symptoms. Meanwhile, if you’re exposed to the virus, they can actually make you sicker. For a truly questionable advantage, that seems like a lot of risk.
Participants in current COVID-19 vaccine trials are not told of this danger in order to go back to where we started, because by having the vaccine they may end up with more serious COVID-19 once they are infected with the virus.
SOURCE :
International Journal of Clinical Practice, October 28, 2020 DOI: 10.111/ijcp.13795 2, 21 PNAS.org April 14, 2020 117 (15) 8218-8221 3 Viral Immunology 2003;16(1):69-86 EBioMedicine 2020 May; 55: 102768 EBioMedicine 2020 May; 55: 102768, Introduction Annals of Internal Medicine September 2, 2020 DOI: 10.7326/M20-5352 YouTube, SARS-CoV-2 and the rise of medical technocracy, Lee Merritt, MD, aprox 8 minutes in (Lie No. 1: Death Risk) Technical Report June 2020 DOI: 10.13140/RG.2.24350.77125
